Eran Broshy
Independent DirectorMr. Eran Broshy was Independent Director of Theravance Biopharma, Inc. from June 02, 2014 to June 12, 2026. Mr. Broshy joined the Theravance Biopharma, Inc. on June 02, 2014. Mr. Broshy is Director of Theravance Biopharma Us, Inc. from June 2014. Mr. Broshy serves as Independent Chairman of the Board at Thirty Madison, Inc. since November 2022. He serves as an Independent Director of Certara, Inc. since July 11, 2022. He serves as Senior Advisor of US at EQT AB (publ) from June 2025. He serves as Chairperson of CluePoints. He also served on the Board of Board Member of Certara. He was an Operating Executive at Tailwind Capital Group, LLC from 2015 to 2021. Mr. Broshy assisted Tailwind in sourcing, evaluating and performing due diligence on healthcare opportunities. He was a strategically focused senior healthcare executive, who has built leading high-growth public and private healthcare businesses as Strategist, Chief Executive Officer, Board Director and private equity Investor. Mr. Broshy has management exposure within the healthcare industry. From March 2013 to August 2015, he worked with Linden Capital Partners. Mr. Broshy is an accomplished veteran Board Director and private equity operating executive with wide exposure working broadly across healthcare. Mr. Broshy was an Executive Advisor at Court Square Capital from 2013 to 2015. He was an Operating Partner at Linden LLC and Linden Capital Partners, where he focused on pharmaceutical services from 2013 to 2015. He served as a Senior Advisor of Providence Equity Partners LLC from June 2006 until December 2012, where he supported its healthcare information investment efforts. He joined Providence Equity Partners in 2009. He served as the Chief Executive Officer and Chairman of inVentiv Health, Inc. from June 1999 to June 11, 2008. Mr. Broshy previously served for over a decade as the Chief Executive Officer (until 2008) and Chairman of the Board of Directors (until 2010) of inVentiv Health, Inc., a privately held company (and until August 2010 a Nasdaq listed company) that delivers a broad range of clinical and commercialization services to pharmaceutical and life sciences companies globally. Mr. Broshy served as an Executive Chairman of inVentiv Health, Inc. since June 11, 2008 and served as the Chairman from June 4, 2006 to June 11, 2008. He took inVentiv public in 1999 and under his leadership transformed inVentiv into the leading provider of clinical and commercialization services to the global pharmaceutical and biotechnology industries, growing revenue in 2008. Mr. Broshy also served for over a decade as Chief Executive Officer and Chairman of inVentiv Health (now part of Syneos Health) and under his leadership the company transformed into the leading global provider of clinical and commercialization services. Mr. Broshy has worked since June 2009 with multiple private equity firms supporting their healthcare investment efforts and on the Board of select portfolio companies, including with Nordic Capital since 2016 and Providence Equity Partners (2009 – 2012). In 2010, Mr. Broshy led the company's go-private transaction. Subsequent to inVentiv Health, Mr. Broshy Partnered with a number of private equity firms to evaluate healthcare investment opportunities. He served as a Managing Partner at The Boston Consulting Group, Inc. where he also served as a management consultant, Vice President, Partner and Health Care Practice Leader. He was at BCG as a management consultant and was responsible for the healthcare practice across the Americas. He was a Partner responsible for its North American healthcare practice. Mr. Broshy consulted with senior executives from a number of major global pharmaceutical manufacturers, managed care organizations and academic medical centers, provides creative solutions on a range of strategic, organizational and operational issues at Boston Consulting Group. He served as the Chief Executive Officer and President of Coelacanth Chemical Corporation from 1998 to 1999. Mr. Broshy has also served as Chairman of the Board of Directors of Clario (previously ERT) and of DermaRite, both privately-held healthcare companies. He serves as the Chairman of Virtual Radiologic Corp. Mr. Broshy serves as the Chairman of the Board of Directors of ERT. He is an Independent Director of FDNA. He was an Independent Director of Magellan Health Inc. since February 25, 2009 until June 22, 2019. He serves as Member of Advisory Board at FDNA Inc. He has been a Director of Union Street Acquisition Corp., since October 2006. Mr. Broshy serves on the Simon Wiesenthal Center's New York Executive Board. He serves on the MIT Corporation Board and the MIT Science Dean's Advisory Council. He has been Independent Director of Theravance Biopharma, Inc. since June 02, 2014. Mr. Broshy serves on the boards of Thirty Madison, a digital healthcare company. He served as a Director of ikaSystems Corporation. Earlier in his career, he was with The Boston Consulting Group (BCG), where he was a Managing Director and Partner responsible for the firms healthcare practice across the Americas. He served as an Independent Director of inVentiv Health, Inc. since June 1999. He served on the Board of Directors in Coelacanth, ikaSystems, Virtual Radiologic and HeartFlow. He served as an Independent Director of Neurogen Corporation since July 24, 2003. He serves as a Member of the Corporation of the Massachusetts Institute of Technology (“MIT”), as Chairman of the American Friends of the Open University of Israel and on the Board of governors of the American Jewish team. Mr. Broshy has an M.B.A. from Harvard University, an M.S. in Civil Engineering from Stanford University and a B.S. in Civil Engineering from the Massachusetts Institute of Technology.
Positions
- Company NameCertara, Inc.Stock CodeCERTPositionIndependent DirectorColleagues
- RPRobert P. AspburyPresident of Model Informed Discovery & Drug Development
- JEJames E. CashmanIndependent Chairman of the Board
- LELeif E. PedersenSenior Advisor
- AKAdrian K. McKemeyPresident of Development Strategy & Evidence
- JRJon ResnickCEO & Director
- JPJulien PerrierPresident & Chief Commercial Officer
- MMMatthew M. WalshIndependent Director
- NKNancy KilleferIndependent Director
